- cafead   Oct 11, 2022 at 04:22: PM
via It has been a tumultuous few months for Gilead Sciences’ breast cancer med Trodelvy. But after a surprise comeback at ESMO this year that reignited blockbuster hopes for the franchise, the antibody-drug conjugate is keeping its winning streak rolling.
article source
article source